Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 905 participants.

Also called NCT01516879

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 905 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01516879
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Hungary, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01516879. Randomized; quadruple masking; primary purpose treatment. Start 2012-01-05 (actual); primary completion 2013-10-14 (actual). Results posted on 2015-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Acronym
DESCARTES
Condition
Hypercholesterolemia
Intervention (Biological)
Evolocumab
Intervention (Biological)
Placebo
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Ezetimibe
Intervention (Other)
Diet Only
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01516879
Content hash
de1d1db7b8fdd4725b41e05f1ff96d77f0288e078d57e2d99ee8c263d098d3d0